Pipeline
Tavanta is addressing serious medical disorders with limited treatment options by creating novel therapies to improve patients’ lives.
We are currently evaluating commercial opportunites for our late-stage asset, TAVT-45, for prostate cancer.
Our late-stage colorectal product targets anal fissure, a common and very painful condition.
Under our respiratory franchise, we are developing peptide conjugates with an initial focus on cystic fibrosis.
Program
Indication
- Discovery Discovery
- Pre-ind Pre-ind
- Ph 1 Ph 1
- Ph 2 Ph 2
- Ph 3 Ph 3
- Approval Approval